Here are five takeaways from the first quarter of 2018:
1. Misonix saw revenue of $7.3 million, an 18 percent boost from the same period the year prior.
2. The company’s U.S. consumables sales rose to $4.1 million, a 25 percent increase compared to the first quarter of 2017.
3. The gross profit was 70.1 percent, up from 69 percent in the first quarter of 2017.
4. Misonix reported a net loss of $1.2 million, or $0.14 per diluted share.
5. The company had cash of $10.5 million with no long-term debt, as of Sept. 30.
More articles on MIS:
Renew Spine Care and SpineMark team up to make MIS spine mainstream
MIS vs. nonsurgical management of sacroiliac joint pain: 4 key findings
Global XLIF surgery market to hit $2.6B by 2024 — 6 observations
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
